Journal of Nippon Medical School: Vol.71 No.4 page.270

Journal of Nippon Medical School

Select Language
in Japanese < > in English

Full Text of this Article

in English PDF (129K)

ArticleTitle Abnormalities of p51, p53, FLT3 and N-ras Genes and Their Prognostic Value in Relapsed Acute Myeloid Leukemia

AuthorList Hiroyuki Nakamura, Koiti Inokuchi, Hiroki Yamaguchi and Kazuo Dan

Affiliation Division of Hematology, Third Department of Internal Medicine, Nippon Medical School

Language EN

Volume 71

Issue 4

Year 2004

Page 270-278

Received January 21, 2004

Accepted April 5, 2004

Keywords gene mutation, acute myeloid leukemia, relapse, prognosis

Abstract
To clarify the role of the genetic mutations in the clinical course of acute myeloid leukemias (AML), we analyzed for p51, p53, FLT3 and N-ras gene mutations and the expression of the p51 gene in relapsed AML. Paired samples obtained from patients with AML at both stages of diagnosis and first relapse were analyzed. Twenty-four patients with relapsed AML survived for 6 to 81 months (median 24 months) from diagnosis. In one patient, no point mutation of the p51 gene was detected, but loss of the p51 gene expression was observed at both stages. Point mutations of the p53 gene were positive at both stages (+/+) in two patients and negative at diagnosis and positive at relapse (-/+) in two patients. Tandem duplication of the FLT3 gene was detected in five patients at both stages (+/+). N-ras gene mutations at both stages (+/+) were detected in three patients. Mutant p53 at relapse was associated with short survival in patients with relapsed AML (P<0.014). Our findings show that p53 mutations were, at least in part, associated with the mechanism of relapse in AML, while new p51, FLT3 and N-ras gene alterations did not occur at relapse. Loss of the p51 gene expression in de novo AML has not been reported yet.

Correspondence to Koiti Inokuchi, Division of Hematology, Third Department of Internal Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan
inokuchi@nms.ac.jp

ArticleTitle	Abnormalities of p51, p53, FLT3 and N-ras Genes and Their Prognostic Value in Relapsed Acute Myeloid Leukemia
AuthorList	Hiroyuki Nakamura, Koiti Inokuchi, Hiroki Yamaguchi and Kazuo Dan
Affiliation	Division of Hematology, Third Department of Internal Medicine, Nippon Medical School
Language	EN
Volume	71
Issue	4
Year	2004
Page	270-278
Received	January 21, 2004
Accepted	April 5, 2004
Keywords	gene mutation, acute myeloid leukemia, relapse, prognosis
Abstract	To clarify the role of the genetic mutations in the clinical course of acute myeloid leukemias (AML), we analyzed for p51, p53, FLT3 and N-ras gene mutations and the expression of the p51 gene in relapsed AML. Paired samples obtained from patients with AML at both stages of diagnosis and first relapse were analyzed. Twenty-four patients with relapsed AML survived for 6 to 81 months (median 24 months) from diagnosis. In one patient, no point mutation of the p51 gene was detected, but loss of the p51 gene expression was observed at both stages. Point mutations of the p53 gene were positive at both stages (+/+) in two patients and negative at diagnosis and positive at relapse (-/+) in two patients. Tandem duplication of the FLT3 gene was detected in five patients at both stages (+/+). N-ras gene mutations at both stages (+/+) were detected in three patients. Mutant p53 at relapse was associated with short survival in patients with relapsed AML (P<0.014). Our findings show that p53 mutations were, at least in part, associated with the mechanism of relapse in AML, while new p51, FLT3 and N-ras gene alterations did not occur at relapse. Loss of the p51 gene expression in de novo AML has not been reported yet.
Correspondence to	Koiti Inokuchi, Division of Hematology, Third Department of Internal Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan inokuchi@nms.ac.jp